Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
about
Simultaneous analysis of quality of life and survival data.Survival, quality-adjusted survival, and other clinical end points in older advanced non-small-cell lung cancer patients treated with albumin-bound paclitaxel.Visualization and dynamics of multidimensional health-related quality-of-life-adjusted overall survival: a new analytic approach.Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians.Adjuvant treatment in node-negative, postmenopausal breast cancer.A Q-TWiST analysis comparing panitumumab plus best supportive care (BSC) with BSC alone in patients with wild-type KRAS metastatic colorectal cancer.Node negative breast cancer.On-going clinical trials for elderly patients with a hematological malignancy: are we addressing the right end points?Patient reported outcomes as endpoints in medical research.Q-TWiST analysis to estimate overall benefit for patients with metastatic renal cell carcinoma treated in a phase III trial of sunitinib vs interferon-α.Cancer clinical outcomes for minority ethnic groups.Subjective health estimations (SHE) in patients with advanced breast cancer: an adapted utility concept for clinical trials.Randomized trial comparing protracted infusion of 5-fluorouracil with weekly doxorubicin and cyclophosphamide with a monthly bolus FAC regimen in metastatic breast carcinoma (SPM90)Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in GermanyQuality of life and quality-adjusted survival (Q-TWiST) in patients receiving dose-intensive or standard dose chemotherapy for high-risk primary breast cancer.Patterns of recurrence of early breast cancer according to estrogen receptor status: a therapeutic target for a quarter of a centuryQuantifying trade-offs: quality of life and quality-adjusted survival in a randomised trial of chemotherapy in postmenopausal patients with lymph node-negative breast cancer.Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma.A uniform procedure for reimbursing the off-label use of antineoplastic drugs according to the value-for-money approach.Patient-Centered Outcome Measures in Lung Cancer Trials.Recommendations for benefit-risk assessment methodologies and visual representations.Are methods for estimating QALYs in cost-effectiveness analyses improving?Therapeutic intervention based on circulating tumor cell phenotype in metastatic breast cancer: concept of the DETECT study program.Quality of life assessment in clinical cancer research.Adjuvant treatment for breast cancer: the overview.Cancer chemotherapy and quality of life.Cancer treatment: deciding what we can afford.Asymptotic properties of mean survival estimate based on the Kaplan-Meier curve with an extrapolated tail.Quality adjusted survival analysis with repeated quality of life measures.A Systematic Review of Health-Related Quality of Life Reporting in Ovarian Cancer Phase III Clinical Trials: Room to Improve.Ethical issues in oncology biostatistics.Quality-adjusted survival (Q-TWiST) analysis of EORTC trial 30853: comparing goserelin acetate and flutamide with bilateral orchiectomy in patients with metastatic prostate cancer. European Organization for Research and Treatment of Cancer.
P2860
Q30683556-E7F4F33E-FB7A-48EA-8528-984BA0112F01Q33423320-E6BBDB4D-A916-4453-9091-CB804FB2BAA8Q33656552-236D582E-8705-4BED-BC70-528D43D80EE1Q33990818-48BD8BC8-6CDB-4BB5-A348-6CEFEE67BC7EQ34385424-0D9D4B94-58A6-49EB-BC20-D67D71F53796Q35034768-12236A66-9AF2-4533-A632-063235F2BE74Q35167731-163DBE7F-E679-4DC9-90D0-B166AFED73BAQ35611941-A3A788ED-78EF-4DB7-A9C6-A3E7D63D8D23Q35739677-7A1CA81D-14BA-4876-A4F2-9ABCDF26A22FQ35949737-FDBBA003-9FAE-4A10-B5CD-F325BBA9A2EEQ36291551-BF66E543-5EF5-40D7-8CB2-696657BACF82Q36292207-E8E303DE-A984-4604-B4F9-AECEAB858FE6Q36292466-0EB11D9D-AD65-4735-AD21-ED8FE5C5EFC2Q36300175-E0651170-597E-498F-9895-C623A59400F9Q36608806-D69CB3BC-DA2C-49B9-A3F1-4C8A39AFC437Q36659068-B14641AD-E3DC-49F6-BD9E-B5FC64043306Q36695170-6F0589ED-9F1A-42EB-9DCC-7264D5C3F8BCQ37003295-716B4B54-260F-4C3B-9DC6-45D6AC8419D3Q37875562-8705862B-32E0-4712-92BE-5DCD5CB0F39DQ38861635-9AC7CF22-8A27-4B5E-B0CF-DA7F0328A506Q40072719-78F1C1AD-C7ED-4B07-889E-1DD2863B7309Q40880162-DE7E5475-C240-4FF7-8BC0-D9AB9706B1F8Q41382683-A016ABB2-1CA8-48C7-AF27-388BECA384E4Q42590178-DEB31576-70DB-4902-B942-7D6E73424273Q42721029-123D7AD6-9DFE-4A20-8329-B9508B68875EQ42763992-925D23D7-9269-4D0D-B784-F6D6942336A3Q43165704-31F240CE-5367-4FD2-B384-25F207B5FBC0Q43493366-FFDED12E-C4ED-4B15-B64B-5D5985280BA4Q44026353-5CAA3B56-1A35-45EC-9EA0-39C2F821DB3FQ47629735-BE872DA3-1068-41D1-921E-C3C8A3842CDBQ52944236-320382AB-75D1-4F67-9804-ABC82575FA8BQ53558519-FF3B6A83-A9E2-4702-B803-81066831C6D3
P2860
Costs and benefits of adjuvant therapy in breast cancer: a quality-adjusted survival analysis.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh-hant
name
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@en
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@nl
type
label
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@en
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@nl
prefLabel
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@en
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@nl
P2093
P356
P1476
Costs and benefits of adjuvant ...... ty-adjusted survival analysis.
@en
P2093
A Goldhirsch
A S Coates
R D Gelber
P356
10.1200/JCO.1989.7.1.36
P407
P577
1989-01-01T00:00:00Z